LC Sciences

LC Sciences is a global biotechnology company providing products and services to genomics and proteomics researchers across an array of markets for nucleic acid/protein analysis, biomarker-discovery and drug development. Our innovative products and comprehensive services are based on several unique, core technology platforms developed by the scientists here at LC Sciences. A wide range of microarray service products are based on our µParaflo® microfluidic on-chip synthesis technology. This technology enables us to provide unique and customizable arrays of oligonucleotides, peptides, and their analog molecules. Our line of microarray services includes microRNA profiling, custom oligonucleotide (aptamer) screening, and peptide arrays for epitope mapping, protein kinase substrate profiling, and phosphopeptide binding assays.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

FUJIFILM DIOSYNTH BIOTECHNOLOGIES TO SUPPORT COVID-19 VACCINE CANDIDATE MANUFACTURING

FUJIFILM Diosynth Biotechnologies | July 28, 2020

news image

FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and gene therapies, announced today that its College Station, Texas, site will support COVID-19 vaccine candidate manufacturing, as part of Operation Warp Speed, a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 to the U.S. population.The Biomedical Advanced Research and Development Auth...

Read More

MOLECULIN ANNOUNCES DISCOVERY OF SIGNIFICANT IN VITRO ACTIVITY AGAINST SARS-COV-2

Moleculin | September 29, 2020

news image

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced that its research team has discovered that a molecule within its portfolio of antimetabolites has displayed significant in vitro antiviral activity against SARS-CoV-2. Independent laboratory testing of the new drug candidate, called "WP1096," has now repea...

Read More

MEDICAL

HEALTHMYNE'S RADIOMIC TECHNOLOGY LEVERAGED TO IDENTIFY BIOMARKERS THAT PREDICT IMMUNOTHERAPY TREATMENT RESPONSES

HealthMyne | September 22, 2021

news image

HealthMyne, a pioneer in applied radiomics, announced that peer-reviewed research recently published in the journal Cancers has demonstrated the ability of its radiomics technology to identify biomarkers that predict whether patients with lung adenocarcinoma would benefit from immunotherapy. In the Cancers article, researchers led by Vincenza Granata evaluated HealthMyne's technology as a quantitative imaging decision support tool for radiomic analysis of lung adenocarcinoma i...

Read More

MEDICAL

SUONO BIO, INC. ANNOUNCES FORMULATION-AGNOSTIC PLATFORM FOR THE DELIVERY OF RNA THERAPEUTICS

Suono Bio | January 06, 2022

news image

Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, announced its latest publication in the Journal of Pharmaceutical Sciences demonstrating the capability to deliver unformulated RNA therapeutics against relevant disease targets in the gastrointestinal tract. This latest publication adds to the validation of Suono Bio’s therapeutic delivery platform leveraging low-frequency ultrasound for formulation-agnostic delivery. This technology wa...

Read More
news image

FUJIFILM DIOSYNTH BIOTECHNOLOGIES TO SUPPORT COVID-19 VACCINE CANDIDATE MANUFACTURING

FUJIFILM Diosynth Biotechnologies | July 28, 2020

FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and gene therapies, announced today that its College Station, Texas, site will support COVID-19 vaccine candidate manufacturing, as part of Operation Warp Speed, a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 to the U.S. population.The Biomedical Advanced Research and Development Auth...

Read More
news image

MOLECULIN ANNOUNCES DISCOVERY OF SIGNIFICANT IN VITRO ACTIVITY AGAINST SARS-COV-2

Moleculin | September 29, 2020

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced that its research team has discovered that a molecule within its portfolio of antimetabolites has displayed significant in vitro antiviral activity against SARS-CoV-2. Independent laboratory testing of the new drug candidate, called "WP1096," has now repea...

Read More
news image

MEDICAL

HEALTHMYNE'S RADIOMIC TECHNOLOGY LEVERAGED TO IDENTIFY BIOMARKERS THAT PREDICT IMMUNOTHERAPY TREATMENT RESPONSES

HealthMyne | September 22, 2021

HealthMyne, a pioneer in applied radiomics, announced that peer-reviewed research recently published in the journal Cancers has demonstrated the ability of its radiomics technology to identify biomarkers that predict whether patients with lung adenocarcinoma would benefit from immunotherapy. In the Cancers article, researchers led by Vincenza Granata evaluated HealthMyne's technology as a quantitative imaging decision support tool for radiomic analysis of lung adenocarcinoma i...

Read More
news image

MEDICAL

SUONO BIO, INC. ANNOUNCES FORMULATION-AGNOSTIC PLATFORM FOR THE DELIVERY OF RNA THERAPEUTICS

Suono Bio | January 06, 2022

Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, announced its latest publication in the Journal of Pharmaceutical Sciences demonstrating the capability to deliver unformulated RNA therapeutics against relevant disease targets in the gastrointestinal tract. This latest publication adds to the validation of Suono Bio’s therapeutic delivery platform leveraging low-frequency ultrasound for formulation-agnostic delivery. This technology wa...

Read More